Epizyme, Inc. (EPZM)
(Delayed Data from NSDQ)
$12.10 USD
+0.19 (1.60%)
Updated May 3, 2019 04:00 PM ET
After-Market: $12.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.10 USD
+0.19 (1.60%)
Updated May 3, 2019 04:00 PM ET
After-Market: $12.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal
by Zacks Equity Research
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
by Zacks Equity Research
Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.
Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen
by Zacks Equity Research
Ipsen, through its wholly-owned subsidiary, is set to acquire Epizyme (EPZM) for $1.45 per share, in cash, along with a contingent value right of $1 per share. The transaction is likely to close by third-quarter 2022.
Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?
by Zacks Equity Research
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates
by Zacks Equity Research
Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates. EPZM has multiple pipeline readouts on track for this year.
Epizyme (EPZM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of -11.43% and 19.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of -31.75% and 86.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
by Kanishka Das
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
Epizyme (EPZM) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Epizyme (EPZM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Is Epizyme (EPZM) Down 29.7% Since Last Earnings Report?
by Zacks Equity Research
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Voyager Therapeutics (VYGR) Surges 12.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why
by Zacks Equity Research
Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the target remains an overhang.
Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag
by Zacks Equity Research
Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. Nevertheless, the pipeline progress is encouraging.
Epizyme (EPZM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of -19.51% and 50.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Allakos (ALLK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Allakos' (ALLK) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's lead pipeline candidate, lirentelimab.
Is a Surprise Coming for Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme (EPZM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Epizyme (EPZM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Epizyme (EPZM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down 54.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Epizyme (EPZM)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Epizyme (EPZM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Epizyme (EPZM) Stock Dives on Public Offering of Common Stock
by Zacks Equity Research
Epizyme (EPZM) to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.
Epizyme (EPZM) Q3 Loss Wider Than Expected, Revenues Up
by Zacks Equity Research
Epizyme (EPZM) posts a wider-than-expected loss in the third quarter and revenues miss estimates. Nevertheless, the pipeline progress is encouraging.
Epizyme (EPZM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of -42.22% and -40.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Epizyme (EPZM) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Epizyme's (EPZM) Tazverik Aids Growth, Overdependence a Woe
by Zacks Equity Research
While Epizyme (EPZM) gets a significant boost with the approval of Tazverik for the treatment of follicular lymphoma and epithelioid sarcoma, the sole dependence on Tazverik for growth remains a woe.